Journal of Inflammation Research (Jul 2022)
Modified Glasgow Prognostic Score is Better for Predicting Oncological Outcome in Patients with Soft Tissue Sarcoma, Compared to High-Sensitivity Modified Glasgow Prognostic Score
Abstract
Tomoki Nakamura, Kunihiro Asanuma, Tomohito Hagi, Akihiro Sudo Department of Orthopedic Surgery, Mie University Graduate School of Medicine, Tsu City, Mie, 514-8507, JapanCorrespondence: Tomoki Nakamura, Department of Orthopaedic Surgery, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu City, Mie, 514-8507, Japan, Tel +81592315022, Fax +81592315211, Email [email protected]: Inflammation plays a critical role in the development, progression, clinical presentation, and diagnosis of tumours. We compared the usefulness of the high-sensitivity modified Glasgow prognostic score (HS-mGPS) and mGPS in predicting oncological outcomes in patients with soft tissue sarcomas (STSs) who underwent primary surgical tumour resection.Methods: Between 2002 and 2018, 144 patients were included in the study. The mean age of the patients was 63 years. The mean follow-up period was 76 months.Results: The disease-specific survival (DSS) at five years was 71.5% in all patients. When patients were divided into three groups according to the HS-mGPS and mGPS, those with a score of 1 or 2 had a poorer DSS than those with a score of 0, respectively. When we compared the survival rate among the 98 patients with both HS-mGPS and mGPS of 0 and 21 patients with HS-mGPS of 1 and mGPS of 0, there was no significant difference in the prognosis. In multivariate analysis, larger tumour size and higher mGPS remained significant.Conclusion: mGPS is a reliable system for identifying patients at high risk for death in patients with STSs.Keywords: soft tissue sarcoma, modified Glasgow prognostic score, high-sensitivity modified Glasgow prognostic score, oncological outcome, C-reactive protein, albumin
